0000899243-17-022447.txt : 20170922
0000899243-17-022447.hdr.sgml : 20170922
20170922173101
ACCESSION NUMBER: 0000899243-17-022447
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170914
FILED AS OF DATE: 20170922
DATE AS OF CHANGE: 20170922
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sirgo Mark A
CENTRAL INDEX KEY: 0001301715
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-31361
FILM NUMBER: 171098302
MAIL ADDRESS:
STREET 1: C/O BIODELIVERY SCIENCES INTERNATIONAL
STREET 2: 801 CORPORATE CENTER DRIVE -SUITE 210
CITY: RALEIGH
STATE: NC
ZIP: 27607
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIODELIVERY SCIENCES INTERNATIONAL INC
CENTRAL INDEX KEY: 0001103021
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 352089858
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4131 PARKLAKE AVENUE
STREET 2: SUITE 225
CITY: RALEIGH
STATE: NC
ZIP: 27612
BUSINESS PHONE: 919 582 9050
MAIL ADDRESS:
STREET 1: 4131 PARKLAKE AVENUE
STREET 2: SUITE 225
CITY: RALEIGH
STATE: NC
ZIP: 27612
FORMER COMPANY:
FORMER CONFORMED NAME: MAS ACQUISITION XXIII CORP
DATE OF NAME CHANGE: 20000111
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-09-14
0
0001103021
BIODELIVERY SCIENCES INTERNATIONAL INC
BDSI
0001301715
Sirgo Mark A
C/O BIODELIVERY SCIENCES INTL, INC.,
4131 PARKLAKE AVENUE, SUITE 225
RALEIGH
NC
27612
1
1
0
0
President and CEO
Common Stock
2017-09-14
4
S
0
50000
2.95
D
1509262
D
Common Stock
2017-09-15
4
M
0
45421
1.78
A
1554683
D
Common Stock
2017-09-15
4
M
0
33026
1.96
A
1587709
D
Common Stock
2017-09-15
4
S
0
54833
2.90
D
1532876
D
Common Stock
2017-09-18
4
S
0
6000
2.85
D
1526876
D
Common Stock
2017-09-19
4
M
0
13661
2.01
A
1540537
D
Common Stock
2017-09-19
4
S
0
24516
2.75
D
1516022
D
Common Stock
2017-09-20
4
M
0
25000
2.26
A
1541022
D
Common Stock
2017-09-20
4
M
0
34265
2.43
A
1575286
D
Common Stock
2017-09-20
4
S
0
65405
2.75
D
1509881
D
Common Stock
2017-09-21
4
S
0
619
2.75
D
1509262
D
Options
1.78
2017-09-15
4
M
0
45421
0.00
D
2013-02-09
2022-02-09
Common Stock
45421
0
D
Options
1.96
2017-09-15
4
M
0
33026
0.00
D
2013-02-15
2022-02-15
Common Stock
33026
0
D
Options
2.01
2017-09-19
4
M
0
13661
0.00
D
2009-07-24
2018-07-24
Common Stock
6902
0
D
Options
2.26
2017-09-20
4
M
0
25000
0.00
D
2011-07-21
2020-07-21
Common Stock
25000
0
D
Options
2.43
2017-09-20
4
M
0
34265
0.00
D
2011-07-21
2020-07-21
Common Stock
34265
0
D
On September 14, 2017, the Reporting Person sold an aggregate of 50,000 shares of the Issuer's Common Stock at a weighted average price of $2.95 per share. The highest sale price for the Common Stock was $2.98 per share and the lowest sale price was $2.90 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The options exercised were acquired from September 15, 2017 to September 19, 2017.
The options exercised were acquired from September 19, 2017 to September 20, 2017.
The options exercised were acquired from September 20, 2017 to September 21, 2017.
On September 20, 2017, the Reporting Person sold an aggregate of 65,405 shares of the Issuer's Common Stock at a weighted average price of $2.75 per share. The highest sale price for the Common Stock was $2.78 per share and the lowest sale price was $2.75 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The Form 4 was due on September 18, 2017 but filed on September 22, 2017 to accommodate multiple connected transactions over several days all on one concise Form 4.
/s/ Mark A. Sirgo
2017-09-22